Integrated care pathways and the hub-and-spoke model for the management of non-melanoma skin cancer: A proposal of the Italian Association of Hospital Dermatologists (ADOI)
暂无分享,去创建一个
C. Massone | L. Naldi | E. Dellambra | P. Marchetti | F. Sampogna | F. Passarelli | T. Tartaglione | F. Fantini | D. Abeni | F. Cusano | L. Fania | Tonia Samela | R. Morese | Marino Maggiore | P. Gentile | M. Falchetto Osti | S. Pallotta | ADOI steering group*
[1] I. Zalaudek,et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. , 2019, European journal of cancer.
[2] C. Schmults,et al. Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women's Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. , 2019, JAMA dermatology.
[3] H. C. de Vijlder,et al. Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study , 2018, The British journal of dermatology.
[4] E. Dellambra,et al. Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches , 2020, Biomedicines.
[5] J. Gehl,et al. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases , 2018, Acta oncologica.
[6] J. Schachter,et al. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Dummer,et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. , 2015, The Lancet. Oncology.
[8] R. Carroll,et al. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. , 1989, The Journal of dermatologic surgery and oncology.
[9] P. Steijlen,et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. , 2013, The Lancet. Oncology.
[10] R. Griffiths,et al. Audit of clinical and histological prognostic factors in primary invasive squamous cell carcinoma of the skin: assessment in a minimum 5 year follow-up study after conventional excisional surgery. , 2002, British journal of plastic surgery.
[11] S. Devarakonda. Hub and spoke model: making rural healthcare in India affordable, available and accessible. , 2016, Rural and remote health.
[12] J. Bernhard,et al. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. , 2009, Archives of dermatology.
[13] Gregor Sersa,et al. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. , 2016, European journal of cancer.
[14] A. Hauschild,et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[15] W. High,et al. Intralesional agents in the management of cutaneous malignancy: a review. , 2011, Journal of the American Academy of Dermatology.
[16] B. Schönfisch,et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. , 2008, The Lancet. Oncology.
[17] L. Golitz,et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. , 2004, Journal of the American Academy of Dermatology.
[18] O. Hansen,et al. Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature. , 1996, Acta oncologica.
[19] E. Epstein,et al. Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice. , 2011, Cancer cell.
[20] M. Leader,et al. Review of high‐risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology , 2017, Head & neck.
[21] V. Gebski,et al. Squamous cell carcinoma of the lip: is there a role for adjuvant radiotherapy in improving local control following incomplete or inadequate excision? , 2003, ANZ journal of surgery.
[22] G. Goldenberg,et al. Basal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical Therapies. , 2016, The Journal of clinical and aesthetic dermatology.
[23] A. Hauschild,et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. , 2017, European journal of cancer.
[24] K. Gross,et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. , 2002, Journal of the American Academy of Dermatology.
[25] J. Leonardi-Bee,et al. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies , 2013, BMJ.
[26] R. Dummer,et al. Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[27] P. Broganelli,et al. Usefulness of Photodynamic Therapy as a Possible Therapeutic Alternative in the Treatment of Basal Cell Carcinoma , 2015, International journal of molecular sciences.
[28] S. Shumack,et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. , 2002, Archives of dermatology.
[29] Aleksandar Sekulic,et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.
[30] E. G. Kuflik. Cryosurgery for Skin Cancer: 30‐Year Experience and Cure Rates , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[31] C. Barker,et al. Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and prevention. , 2019, Journal of the American Academy of Dermatology.
[32] K. Peris,et al. Update of the European guidelines for basal cell carcinoma management , 2014, European Journal of Dermatology.
[33] I. Zalaudek,et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. , 2020, European journal of cancer.
[34] A. Hauschild,et al. PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma , 2018, The New England journal of medicine.
[35] S. Porceddu. Prognostic factors and the role of adjuvant radiation therapy in non-melanoma skin cancer of the head and neck. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[36] F. Lacarrubba,et al. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome , 2003, Clinical and experimental dermatology.
[37] M. Cristofolini,et al. Epidemiology of Skin Tumors: Data from the Cutaneous Cancer Registry in Trentino, Italy , 2003, Journal of cutaneous medicine and surgery.
[38] A. Hauschild,et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study , 2017, BMC Cancer.
[39] D. Ekwueme,et al. Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer , 2011, PharmacoEconomics.
[40] D. Brodland,et al. Surgical margins for excision of primary cutaneous squamous cell carcinoma. , 1992, Journal of the American Academy of Dermatology.
[41] E. Dellambra,et al. [The integrated care pathway for non melanoma skin cancer: the Istituto Dermopatico dell'Immacolata - IRCCS experience in Rome.] , 2020, Recenti progressi in medicina.
[42] P. Steijlen,et al. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial. , 2016, The Journal of investigative dermatology.
[43] P. Ascierto,et al. Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis , 2017, Journal of Translational Medicine.
[44] A. Testori,et al. Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach , 2010, Dermatologic therapy.
[45] Roma H. Patel,et al. Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma , 2019, American Journal of Clinical Dermatology.
[46] A. Hauschild,et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing , 2020, Journal for immunotherapy of cancer.
[47] A. Guminski,et al. Immunotherapy and other systemic therapies for cutaneous SCC. , 2019, Oral oncology.
[48] J. Fortenberry,et al. The hub-and-spoke organization design: an avenue for serving patients well , 2017, BMC Health Services Research.
[49] J. Hercogová,et al. Superpulsed CO2 Laser Treatment of Basal Cell Carcinoma With Intraoperatory Histopathologic and Cytologic Examination , 2002, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[50] E. Dennett,et al. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors , 2012, Journal of surgical oncology.
[51] A. Sidoroff,et al. European Dermatology Forum guidelines on topical photodynamic therapy , 2015, European Journal of Dermatology.
[52] E. Dellambra,et al. Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches , 2021, Biomedicines.
[53] L. Buchmann,et al. Elective Neck Dissection for Head and Neck Cutaneous Squamous Cell Carcinoma with Skull Base Invasion , 2017, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[54] D. Leffell,et al. Management of nonmelanoma skin cancer in 2007 , 2007, Nature Clinical Practice Oncology.
[55] S. Mocellin,et al. Basal cell carcinoma: 10-year experience with electrochemotherapy , 2017, Journal of Translational Medicine.
[56] Konstantin Moskalik,et al. The efficacy of facial skin cancer treatment with high-energy pulsed neodymium and Nd:YAG lasers. , 2009, Photomedicine and laser surgery.
[57] A. Hauschild,et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. , 2021, The Lancet. Oncology.
[58] Ivan Buzurovic,et al. Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. , 2019, Practical radiation oncology.
[59] C. Berking,et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. , 2020, The Lancet. Oncology.
[60] Q. Kan,et al. Comparison between wait-and-see policy and elective neck dissection in clinically N0 cutaneous squamous cell carcinoma of head and neck , 2018, Medicine.
[61] R. Schwartz,et al. Topical pharmacotherapy for skin cancer: part I. Pharmacology. , 2014, Journal of the American Academy of Dermatology.
[62] H. Williams,et al. Interventions for basal cell carcinoma of the skin: systematic review , 2004, BMJ : British Medical Journal.
[63] M. W. M. Jaspers,et al. Two Decades of Teledermatology: Current Status and Integration in National Healthcare Systems , 2016, Current Dermatology Reports.